All In Biotech

Drug Trial Radar · NCT05142189

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Jun 17, 2022

Primary completion

Feb 2030

Study completion Nov 2031

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
First posted
Dec 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab, docetaxel, carboplatin, paclitaxel, osimertinib, anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), rearranged during transfection (RET) TKIs, BNT316 (an anti-cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\] antibody), an anti-B7-H3 antibody conjugated to a topoisomerase I inhibitor, an anti-human epidermal growth factor receptor 3 (HER3) antibody conjugated to a topoisomerase I inhibitor or a bispecific antibody for programmed death ligand 1 (PD-L1) and vascular endothelial growth factor A (VEGF-A) in participants with non-small cell lung cancer (NSCLC). The study will comprise several cohorts for dose confirmation in monotherapy as well as in combinations of BNT116 as mentioned above. The study will enroll participants with NSCLC in advanced or metastatic stage in Cohorts 1 to 4 and Cohorts 7 to 10, unresectable NSCLC Stage III in Cohorts 5 and 11, resectable NSCLC of Stage II and III in Cohort 6, advanced/metastatic epidermal growth factor receptor (EGFR)-mutant NSCLC in Cohort EGFR, and advanced/metastatic ALK rearranged or RET rearranged NSCLC in Cohort ALK/RET. Cohort EGFR and Cohort ALK/RET will enroll only at selected sites in the US.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • BNT116Biological

    Intravenous injection

  • CemiplimabBiological

    Intravenous infusion

  • DocetaxelDrug

    Intravenous infusion

  • CarboplatinDrug

    Intravenous infusion

  • PaclitaxelDrug

    Intravenous infusion

  • BNT316Biological

    Intravenous infusion

  • anti-B7-H3 antibody conjugated to topoisomerase I inhibitorBiological

    Intravenous infusion

  • anti-HER3 antibody conjugated to topoisomerase I inhibitorBiological

    Intravenous infusion

  • Bispecific antibody for PD-L1 and VEGF-ABiological

    Intravenous infusion

  • OsimertinibBiological

    Oral

  • ALK-inhibitor or RET-inhibitorBiological

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohorts 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, EGFR and ALK/RET: Occurrence of Dose-Limiting Toxicities (DLTs) During the DLT Observation PeriodTime frame: From first dose of IMP up to 21 days
  2. Cohorts 1 to 11, EGFR and ALK/RET: Occurrence of Treatment-Emergent Adverse Events (TEAEs) Reported by Relationship, Seriousness, and GradeTime frame: up to 27 months
  3. Cohort 6 only: Occurrence of Post-Surgical Adverse Events (AEs) Related to BNT116 and CemiplimabTime frame: up to 27 months
  4. Cohort 6 only: Occurrence of Treatment-Related Delays to Surgery More Than 9 weeks Post the Last Dose of Neo-Adjuvant TreatmentTime frame: up to 6 months

Locations

45 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Kentucky Chandler Medical Center

    Lexington, Kentucky · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Scientia Clinical Research

    Randwick, New South Wales, Australia · Recruiting

  • Royal North Shore Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Cancer Research SA

    Adelaide, South Australia, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Universitätsklinikum Köln

    Cologne, Germany · Recruiting

  • Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF)

    Frankfurt, Germany · Recruiting

  • University Medical Center Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR

    Mainz, Germany · Recruiting

  • ICON-PRA Budapest, Fázis 1 Vizsgálóhely

    Budapest, Hungary · Completed

  • Semmelweis Egyetem ÁOK Belgyógyászati és Onkológiai Klinika

    Budapest, Hungary · Completed

  • National Institute of Oncology

    Budapest, Hungary · Recruiting

  • Clinexpert Ltd

    Gyöngyös, Hungary · Recruiting

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland · Recruiting

  • Warminsko Mazurskie Centrum Chorob Pluc w Olsztynie

    Olsztyn, Poland · Recruiting

  • NZOZ Medpolonia Sp. Z o.o

    Poznan, Poland · Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

    Warsaw, Poland · Withdrawn

  • Institut Catala d'Oncologia Badalona, Hospital Germans Trias I Pujol

    Badalona, Spain · Recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Recruiting

  • MD Anderson Cancer Center

    Madrid, Spain · Recruiting

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain · Recruiting

  • START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC)

    Madrid, Spain · Recruiting

  • Complejo Hospitalario Universitario de Santiago de Compostela (CHUS) - Hospital Clinico Universitario (University Clinical Hospital)

    Santiago de Compostela, Spain · Recruiting

  • Hospital Universitario Virgen Macarena

    Seville, Spain · Recruiting

  • Hospital Universitario y Politecnico La Fe

    Valencia, Spain · Recruiting

  • Adana City Training and Research Hospital

    Adana, Turkey (Türkiye) · Recruiting

  • Haceteppe Hospital

    Ankara, Turkey (Türkiye) · Recruiting

  • Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital

    Ankara, Turkey (Türkiye) · Recruiting

  • Ankara City Hospital

    Ankara, Turkey (Türkiye) · Recruiting

  • Koc University Hospital

    Istanbul, Turkey (Türkiye) · Recruiting

  • University Medical Faculty Oncology Institute

    Istanbul, Turkey (Türkiye) · Recruiting

  • Yeditepe University

    Istanbul, Turkey (Türkiye) · Recruiting

  • Ege University School of Medicine Tulay Aktas Oncology Hospital

    Izmir, Turkey (Türkiye) · Recruiting

  • Dokuz Eylul Medical School

    Izmir, Turkey (Türkiye) · Completed

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom · Recruiting

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.